跳至主要内容
临床试验/NCT04834167
NCT04834167已完成不适用

OneDoc Picopulse™ for the Treatment of Melasma Among Malaysian Women

Universiti Tunku Abdul Rahman1 个研究点 分布在 1 个国家目标入组 32 人开始时间: 2021年5月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
32
试验地点
1
主要终点
Acceptability of the treatment

研究概览

简要总结

OneDoc Picopulse™ is a radiopulse technology beauty grade device invented for treating melasma.

详细描述

This is a new attempt to evaluate the effectiveness of OneDoc PicopulseTM in treating melasma among women of childbearing age in Klang Valley, Malaysia. This pilot feasibility study protocol is to access feasibility of the OneDoc Picopulse™ in the future definitive trial. The findings of this study would justify OneDoc Picopulse™ as one of the promising alternative treatment for melasma.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Women presenting dermal melasma with Fritzpatrick skin type III to V
  • Malaysian citizen
  • Agreed to participate
  • Provide informed consent

排除标准

  • Patients who had a laser procedure, phototherapy therapy, peel, oral therapy, topical treatment or used lightening creams in the treatment area within the past 6 months.
  • Patients with pregnancy, lactating, active dermatitis, had a history of immunosuppression/immune deficiency disorders
  • Patients who photosensitivity or taking drugs known to induce photosensitivity,
  • Patients that have been exposed to severe sun exposure, having severe epidermal injury, allergy and sensitivity
  • Patients who could not attend follow-up treatments

结局指标

主要结局

Acceptability of the treatment

时间窗: One month

Short Assessment of Patient Satisfaction (SAPS) questionnaire with additional Qualitative data collection; The score range for SAPS is from 0 (extremely dissatisfied) to 28 (extremely satisfied)

次要结局

  • Melasma(Through study completion, an average of 24 weeks)
  • Feasibility of the recruitment and measurement tools(Pre-treatment, two weeks and one month)
  • Treatment adherence(five months)
  • Safety evaluation(immediately after and before each subsequent treatment)
  • Quality of life of patients(Pre-treatment, two weeks and one month post-treatment)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Yang Mooi Lim

Deputy Director (Institute of Postgraduate Studies and Research), Professor

Universiti Tunku Abdul Rahman

研究点 (1)

Loading locations...

相似试验

OneDoc Picopulse™ for the Treatment of Melasma Among... | 临床试验